714273-83-3

Basic information

• Product Name: 1H-Imidazole-4-carboxaldehyde, 5-(1,1-dimethylethyl)- (9CI)
• Synonyms: 1H-Imidazole-4-carboxaldehyde, 5-(1,1-dimethylethyl)- (9CI);4-tert-butyl-1H-iMidazole-5-carbaldehyde;1H-IMidazole-4-carboxaldehyde, 5-(1,1-diMethylethyl)-;5-(1,1-Dimethylethyl)-1H-imidazole-4-carboxaldehyde;1H-Imidazole-5-carboxaldehyde, 4-(1,1-dimethylethyl)-;1H-Imidazole-4-carbaldehyde,5-(1,1-dimethylethyl)-;EOS-62086
• CAS NO: 714273-83-3
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19368
• EINECS: 202-303-5
• Product Categories: ALDEHYDE
• Mol File: 714273-83-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 338.876 °C at 760 mmHg
• Flash Point: 162.978 °C
• Appearance: /
• Density: 1.092 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.53±0.10(Predicted)
• CAS DataBase Reference: 1H-Imidazole-4-carboxaldehyde, 5-(1,1-dimethylethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-4-carboxaldehyde, 5-(1,1-dimethylethyl)- (9CI)(714273-83-3)
• EPA Substance Registry System: 1H-Imidazole-4-carboxaldehyde, 5-(1,1-dimethylethyl)- (9CI)(714273-83-3)

Safety Data

• Hazardous Substances Data: 714273-83-3(Hazardous Substances Data)

Usage

General Description

1H-Imidazole-4-carboxaldehyde, 5-(1,1-dimethylethyl)- (9CI) is a chemical compound with a molecular formula C9H14N2O. It is a derivative of imidazole, a five-membered heterocyclic ring containing three carbon atoms and two nitrogen atoms. This specific derivative contains a carboxaldehyde functional group and a tert-butyl group, which consists of a methyl group attached to three carbon atoms. This chemical is most commonly used as an intermediate or building block in organic synthesis for the preparation of various pharmaceuticals and agricultural chemicals. Its unique structural characteristics make it a valuable component in the production of a wide range of important organic compounds.

Upstream product

• 51721-22-3 (4-(tert-butyl)-1H-imidazol-5-yl)methanol 
• 17094-34-7 ethyl pivaloylacetate 
• 51721-21-2 ethyl 4-(tert-butyl)-1H-imidazole-5-carboxylate 
• 29509-07-7 2-chloro-4,4-dimethyl-3-oxopentanoic acid ethyl ester 
• 714273-89-9 5-(tert-butyl)oxazole-4-carboxylic acid ethyl ester 
• 51721-21-2 5-(tert-butyl)-1H-imidazole-4-carboxylic acid ethyl ester 
• 51721-22-3 (5-(tert-butyl)-1H-imidazol-4-yl)methanol 
• 5469-26-1 1-Bromopinacolon 
• 1538-75-6 2,2-dimethylpropanoic anhydride 

Downstream Products

• 714273-84-4 1-acetyl-3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-2,5-piperazinedione 
• 714272-27-2 (3Z,6Z)-3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene]-6-(phenylmethylene)piperazine-2,5-dione 
• 1367709-16-7 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-phenylmethylidene]-2,5-piperazinedione trifluoroacetate 
• 714272-29-4 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(2-methoxyphenyl)methylidene]-2,5-piperazinedione 
• 1367717-84-7 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(3-methoxyphenyl)methylidene]-2,5-piperazinedione trifluoroacetate 
• 714272-28-3 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(4-methoxyphenyl)methylidene]-2,5-piperazinedione 
• 714272-36-3 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(2,3-dimethoxyphenyl)methyllidene]-2,5-piperazinedione trifluoroacetate 
• 714272-33-0 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(2,4-dimethoxyphenyl)methylidene]-2,5-piperazinedione 
• 1367720-57-7 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(2,5-dimethoxyphenyl)methylidene]-2,5-piperazinedione trifluoroacetate 
• 714272-34-1 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(3,4-dimethoxyphenyl)methylidene]-2,5-piperazinedione 
• 714272-83-0 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(3-methylphenyl)methylidene]-2,5-piperazinedione trifluoroacetate 
• 714272-81-8 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(2-fluorophenyl)methylidene]-2,5-piperazinedione trifluoroacetate 
• 714272-77-2 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(3-fluorophenyl)methylidene]-2,5-piperazinedione trifluoroacetate 
• 714272-75-0 3-{(Z)-1-[5-(tert-butyl)-1H-4-imidazolyl]methylidene}-6-[(Z)-1-(4-fluorophenyl)methylidene]-2,5-piperazinedione trifluoroacetate 

Relevant articles and documents

Preparation method of plinabulin intermediate imidazole formaldehyde compound

The invention discloses a preparation method of an imidazole formaldehyde compound. According to the preparation method, the operation danger level and the production cost are reduced by optimizing and improving a preparation route method, optimizing reaction conditions and improving a post-treatment and purification method; the requirement on the corrosion resistance grade of reaction container equipment is low, the operation safety is good, and the post-treatment is green and environment-friendly; and the preparation method has the advantages of simple operation of each step, safe and feasible solvent and process conditions, realization of environment-friendly production, and wide application prospect.

Plinabulin compound polycrystalline type and preparation method thereof

The invention provides a plinabulin compound polycrystalline type and a preparation method thereof, and particularly relates to a polycrystalline type of (3Z,6Z)-3-benzylidene-6-((5-tert-butyl-1H-imidazole-4-yl) methylene)piperazidine-2,5-diketone and a preparation method thereof. Three kinds of crystalline types beta, gamma and delta are developed on the basis of the crystalline type alpha of (3Z,6Z)-3-benzylidene-6-((5-tert-butyl-1H-imidazole-4-yl) methylene)piperazidine-2,5-diketone, wherein the three kinds of crystalline types beta, gamma and delta can be prepared into monocrystallines; the three kinds of crystalline types have the advantages of clear conformation, high purity and high method repeatability; the important significance is realized on implementation of plinabulin biological effectiveness study and dosage form variety development.

Development of MBRI-001, a deuterium-substituted plinabulin derivative as a potent anti-cancer agent

Plinabulin, a drug targeting microtubule of cancer cells, has been currently tried in its phase III clinical study. However, low efficacy caused by poor pharmacokinetic (PK) properties has been considered to be the main obstacle to approved by the Food and Drug Administration. Herein, we introduced a deuterium atom as an isostere in its structure to become a new compound named (MBRI-001, No. 9 in a series of deuterium-substituted compounds). The structure of MBRI-001 was characterized by HRMS, NMR, IR and a single crystal analysis. MBRI-001 exhibited better pharmacokinetic characteristics than that of plinabulin. Additionally, its antitumor activity is in a low nanomolar level for a variety of cancer cell lines and high activity against human NCI-H460 xenograted in mice intravenous administration. Importantly, continuous administration of MBRI-001 exhibited lower toxicity compared to docetaxel. We thus suggest that MBRI-001 could be developed as a promising anti-cancer agent in near future.